A Study of LY4515100 in Participants With Pain Following Third Molar Removal

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
Eli Lilly and Company
Study ID
NCT07511816
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Acute Pain
  • Molar
  • Molar, Third
  • Surgery, Oral

Eligibility Criteria

Sex
ALL
Age
18 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • LY4515100 — DRUG
    Administered Orally
  • Placebo — DRUG
    Administered Orally

Study Details

The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.

Key Dates

Start date
Apr 1, 2026
Status verified
Apr 2026
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
212 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: LY4515100
    Administered Orally
  • Placebo Comparator: Placebo
    Administered Orally

Primary Outcome Measure

Change from Baseline in Self-Reported Pain Intensity [ Time Frame: Baseline, Up to Day 1 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
JBR Clinical ResearchSalt Lake CityUtah84107
Todd Bertoch (PRINCIPAL_INVESTIGATOR)

Find similar trials in Salt Lake City, UT

By research site
JBR Clinical Research· Salt Lake City, UT

Related Studies